Goldman Sachs sets new Biogen stock price target on bold Alzheimer’s bet
Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics and biosimilars, revenue has trended down, and the stock spent much of 2025 trading near multi-year lows. So when Goldman Sachs steps up with a price target hike to $250, …
Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics and biosimilars, revenue has trended down, and the stock spent much of 2025 trading near multi-year lows. So when Goldman Sachs steps up with a price target hike to $250, …
Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics and biosimilars, revenue has trended down, and the stock spent much of 2025 trading near multi-year lows. So when Goldman Sachs steps up with a price target hike to $250, …
The full story continues on The Street.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.